Branded formulations — large — Business MegaBrands 2026–27

Branded formulations covers prescription medicines and over-the-counter products sold under brand names to doctors, pharmacies and hospitals across India, made in finished dosage forms such as tablets, capsules, injectables and inhalers. The large companies in this group also export generic medicines to regulated markets. Their products and distribution networks shape the availability and cost of everyday medicines across the country.

Slot BMB-166 · Pharmaceuticals · 8 brands in contention · Business MegaBrand: to be announced in 2027

Brands in contention

Listed alphabetically. The order does not reflect evaluation.

CompanyMegaBrands 501
Alkem
CiplaAlso a MegaBrand 501
Intas
Lupin
Mankind
Sun PharmaAlso a MegaBrand 501
Torrent Pharma
Zydus Lifesciences

How this category is evaluated

Every brand in this category is assessed on WCRC's 50-parameter brand evaluation model, across five pillars: Brand Positioning & Recall, Trust & Sentiment, Product, Innovation & Delivery, Sustainability, Governance & ESG, and Digital & Financial Soundness. Scores are compared within the category, and the brand with the strongest result is named the Business MegaBrand. Read the methodology

Frequently asked

Who are the major pharma companies in India?

The brands in contention for large branded pharmaceutical formulations in the Business MegaBrands 2026–27 cohort are Alkem, Cipla, Intas, Lupin, Mankind, Sun Pharma, Torrent Pharma and Zydus Lifesciences. This is a factual list, not a ranking. WCRC will name one Business MegaBrand after its independent 50-parameter evaluation.

Other categories in Pharmaceuticals

All of Pharma, Life Sciences & Medtech · The 2026–27 cohort

Cite this page: WCRC, Business MegaBrands 2026–27, Branded formulations — large (Slot BMB-166), https://www.mostvaluablebrands.com/business-megabrands/2026-27/pharma-life-sciences-and-medtech/branded-formulations-large/, accessed [date].

WCRC network: WCRC International · WCRC Leaders